143 related articles for article (PubMed ID: 30824955)
1. Doripenem versus meropenem as first-line empiric therapy of febrile neutropenia in patients with acute leukemia: a prospective, randomized study.
Oyake T; Takemasa-Fujisawa Y; Sugawara N; Mine T; Tsukushi Y; Hanamura I; Fujishima Y; Aoki Y; Kowata S; Ito S; Ishida Y
Ann Hematol; 2019 May; 98(5):1209-1216. PubMed ID: 30824955
[TBL] [Abstract][Full Text] [Related]
2. A comparative analysis of meropenem and doripenem in febrile patients with hematologic malignancies: a single-center retrospective study.
Toya T; Nannya Y; Narukawa K; Ichikawa M; Kurokawa M
Jpn J Infect Dis; 2012; 65(3):228-32. PubMed ID: 22627304
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
4. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
[TBL] [Abstract][Full Text] [Related]
5. [Risk of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam Compared to Vancomycin and Meropenem or Doripenem: A Retrospective Cohort Study].
Ide N; Sato S; Sawaguchi K
Yakugaku Zasshi; 2019; 139(12):1609-1614. PubMed ID: 31787651
[TBL] [Abstract][Full Text] [Related]
6. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
[TBL] [Abstract][Full Text] [Related]
7. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial.
Feld R; DePauw B; Berman S; Keating A; Ho W
J Clin Oncol; 2000 Nov; 18(21):3690-8. PubMed ID: 11054442
[TBL] [Abstract][Full Text] [Related]
8. Empiric monotherapy for febrile neutropenia--a randomized study comparing meropenem with ceftazidime.
Lindblad R; Rödjer S; Adriansson M; Andreasson B; Bäckström B; Johansson P; Karlsson K; Rhedin C; Turesson I
Scand J Infect Dis; 1998; 30(3):237-43. PubMed ID: 9790130
[TBL] [Abstract][Full Text] [Related]
9. A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia.
Bauduer F; Cousin T; Boulat O; Rigal-Huguet F; Molina L; Fegueux N; Jourdan E; Boiron JM; Reiffers J;
Leuk Lymphoma; 2001 Jul; 42(3):379-86. PubMed ID: 11699402
[TBL] [Abstract][Full Text] [Related]
10. Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia.
Bucaneve G; Micozzi A; Picardi M; Ballanti S; Cascavilla N; Salutari P; Specchia G; Fanci R; Luppi M; Cudillo L; Cantaffa R; Milone G; Bocchia M; Martinelli G; Offidani M; Chierichini A; Fabbiano F; Quarta G; Primon V; Martino B; Manna A; Zuffa E; Ferrari A; Gentile G; Foà R; Del Favero A
J Clin Oncol; 2014 May; 32(14):1463-71. PubMed ID: 24733807
[TBL] [Abstract][Full Text] [Related]
11. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.
Bow EJ; Rotstein C; Noskin GA; Laverdiere M; Schwarer AP; Segal BH; Seymour JF; Szer J; Sanche S
Clin Infect Dis; 2006 Aug; 43(4):447-59. PubMed ID: 16838234
[TBL] [Abstract][Full Text] [Related]
12. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study.
de la Cámara R; Figuera A; Sureda A; Hermida G; Verge G; Olalla I; Fernández Rañada JM; Domingo Albos A
Haematologica; 1997; 82(6):668-75. PubMed ID: 9580087
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders.
Sano H; Kobayashi R; Suzuki D; Hori D; Kishimoto K; Kobayashi K
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27873451
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia.
Stein GE; Kulhanek G; Smith CL; Kuti JL; Nicolau DP; Scharmen A; Farnum C; Tran M; Kalra A; Havlichek DH
Ann Pharmacother; 2012 Oct; 46(10):1281-6. PubMed ID: 23012385
[TBL] [Abstract][Full Text] [Related]
15. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
[TBL] [Abstract][Full Text] [Related]
16. Empiric monotherapy in neutropenia: a realistic goal?
Del Favero A; Bucaneve G; Menichetti F
Scand J Infect Dis Suppl; 1995; 96():34-7. PubMed ID: 7652501
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
Ozkaynak MF; Krailo M; Chen Z; Feusner J
Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
[TBL] [Abstract][Full Text] [Related]
18. Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review.
Cometta A; Glauser MP
J Chemother; 1996 Oct; 8(5):375-81. PubMed ID: 8957718
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of empiric monotherapy with ceftazidime for low-risk grade IV febrile neutropenia after cytotoxic chemotherapy in cancer patients.
Chernobelski P; Lavrenkov K; Rimar D; Riesenberg K; Schlaeffer F; Ariad S; Mermershtain W
Chemotherapy; 2006; 52(4):185-9. PubMed ID: 16675902
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting outcome in high risk febrile neutropenia in patients receiving intensive chemotherapy for acute sleukemia: A prospective, observational study from South India.
Rajendranath R; Balasubramaniyum VK; Vijayakumar V; Ganesan P; Tenali GS
Indian J Cancer; 2014; 51(4):481-6. PubMed ID: 26842171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
